Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Hudyono J.
57192893387;
Renin inhibitor in hypertension treatment: From pharmacological point of view
2011
Medical Journal of Indonesia
20
3
232
237
1
Clinical Study Unit, Faculty of Medicine, University of Indonesia, Indonesia
Hudyono, J., Clinical Study Unit, Faculty of Medicine, University of Indonesia, Indonesia
The use of drugs that inhibit the renin-angiotensin system is one of the effective way to intervene in the pathogenesis of cardiovascular and renal disorders, especially in hypertension treatment. The idea of blocking the renin system at its origin by renin inhibitor has existed for more than 30 years. Renin inhibitor supresses the covension of angiotensinogen into angiotensin, and further deacreases the generation of the active peptide angiotensin II. The first generation (enalkiren) and second generation (remikiren) of orally active renin inhibitors were never used clinically because of low bioavailability and weak blood pressure-lowering activity. At present, aliskiren is the first non-peptide orally active renin inhibitor of the third generation to progress to phase III clinical trials and was approved by U.S. Food and Drug Administration (FDA) in March 2007. Aliskiren becomes the first renin inhibitor with indications for the treatment of hypertension in Indonesia, a compounds with improved oral bioavailability, specificity and efficacy. This review summarises the development of oral renin inhibitors, pharmacological aspects, with a focus on aliskiren. © 2011, Faculty of Medicine, Universitas Indonesia. All rights reserved.
Aliskiren; Hypertension; Renin inhibitor; Renin-angiotensin
aliskiren; amlodipine; angiotensin II; angiotensinogen; atenolol; atorvastatin; celecoxib; cytochrome P450; digoxin; furosemide; hydrochlorothiazide; irbesartan; ketoconazole; metformin; mevinolin; ramipril; remikiren; renin inhibitor; valsartan; warfarin; blood pressure regulation; controlled clinical trial (topic); creatinine clearance; drug absorption; drug accumulation; drug bioavailability; drug efficacy; drug elimination; drug excretion; drug hypersensitivity; drug mechanism; drug safety; drug specificity; heart infarction; hepatic clearance; human; hypertension; lactation; liver metabolism; pharmacodynamics; phase 3 clinical trial (topic); plasma renin activity; pregnancy; randomized controlled trial (topic); renal protection; renin angiotensin aldosterone system; respiratory distre
Faculty of Medicine, Universitas Indonesia
08531773
Review
Q3